Article Text

Download PDFPDF
Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin)
  1. S K Gibran1,
  2. A Sachdev1,
  3. T Stappler1,
  4. R Newsome2,
  5. D Wong1,
  6. P Hiscott1
  1. 1St Paul’s Eye Unit, Royal Liverpool Hospital, Liverpool, UK
  2. 2Department of Ophthalmology, Southampton General Hospital, Southampton, Hampshire, UK
  1. Correspondence to: S K Gibran St Paul’s Eye Unit, Royal Liverpool Hospital, Liverpool L7 8XP, UK; syedgibran{at}


Aim: To report the findings in a patient treated by repeated intravitreal bevacizumab (Avastin) injections, followed by macular relocation and excision of subfoveal choroidal neovascular membrane (CNV).

Methods: Histopathological evaluation of the CNV specimen, including immunohistochemical assessment.

Results: During surgical excision, the CNV seemed to be avascular and its underlying bed did not bleed. Histopathological examination revealed that the CNV comprised avascular fibrous subretinal tissue containing fibroblastic retinal pigment epithelial (RPE) cells, fragments of irregular thickened Bruch’s membrane and fibrotic choroidal tissue containing some medium-sized vessels but no choriocapillaris.

Conclusions: The development of an RPE tear during the course of Avastin treatment may reflect contraction of the avascular subretinal tissue, whereas the lack of capillaries in both choroidal and subretinal components may be caused by the increased access of Avastin to the choriocapillaris in the presence of the RPE tear.

  • AMD, age-related macular degeneration
  • CNV, choroidal neovascular membrane
  • RPE, retinal pigment epithelial
  • VEGF, vascular endothelial growth factor

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 4 January 2007

  • Competing interests: None declared.